Equities

Revelation Biosciences Inc

REVB:NAQ

Revelation Biosciences Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.21
  • Today's Change0.00 / 0.00%
  • Shares traded10.00
  • 1 Year change-92.78%
  • Beta0.1884
Data delayed at least 15 minutes, as of Jun 06 2024 20:59 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Revelation Biosciences, Inc. is a clinical-stage life sciences company engaged in the development of innate immune system therapeutics and diagnostics. Its therapeutic candidates are based on its Gemini formulation of active ingredient phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA) that is known to stimulate Toll-like receptor 4 (TLR-4). Its product candidates include Gemini-SSI, which is being developed for the prevention and treatment of surgical sit infection; Gemini-AKI, which is being developed as a potential therapy for the prevention and treatment of acute kidney injury as a result of cardiac surgery; and Gemini-CKD, which is being developed as a potential therapy for the prevention and treatment of chronic kidney disease. Stimulation of TLR4 via Gemini leads to a controlled production of varied cytokines and chemokines which modulate the activity of the innate and adaptive immune response, relative to Lipopolysaccharides (LPS).

  • Revenue in USD (TTM)0.00
  • Net income in USD-8.96m
  • Incorporated2019
  • Employees9.00
  • Location
    Revelation Biosciences Inc4660 Lajolla Village Drive, Suite 100SAN DIEGO 92122United StatesUSA
  • Phone+1 (650) 800-3717
  • Fax+1 (302) 645-1280
  • Websitehttps://www.revbiosciences.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Biostax Corp0.00-1.57m2.93m-----------0.0188-0.01880.00-0.0580.00-------390.77-81.51---------------6.05--------53.32------
Veritas Farms Inc730.65k-6.15m2.93m17.00--14.49--4.01-0.1319-0.13190.01360.00130.08770.80647.8042,979.41-69.02-72.11-123.21-93.59-220.0924.07-787.27-177.790.1392-5.560.95---63.42-0.942723.68---52.93--
ENDRA Life Sciences Inc0.00-9.89m2.97m21.00--0.7939-----1.26-1.260.000.33880.00----0.00-168.89-132.00-228.29-157.28------------0.00------23.67---19.46--
Mosaic Immunoengineering Inc0.00-897.69k3.04m3.00---------0.1245-0.12450.00-0.84980.00----0.00-789.46-----------------26.91--------57.65------
Resonate Blends Inc101.41k-4.72m3.13m6.00------30.82-0.0537-0.05370.0012-0.00070.0328-------152.56-680.29-----34.87-78.88-4,657.83-12,895.26---0.74131.02---66.73-56.57-316.63------
Seelos Therapeutics Inc1.97m-27.12m3.13m10.00------1.59-44.59-44.592.16-17.360.1449--2.24131,600.00-198.99-180.05---386.76-----1,373.61-9,612.88------------48.48------
Revelation Biosciences Inc0.00-8.96m3.15m9.00--0.3327-----32.09-32.090.005.800.00----0.00-54.61---91.95--------------0.00------98.89------
Sonoma Pharmaceuticals Inc12.31m-5.08m3.19m9.00--0.4186--0.2595-0.9608-0.96081.950.4890.86252.584.761,367,778.00-35.56-37.52-47.14-51.3539.1740.17-41.23-37.123.11--0.0065--5.10-4.44-1.28--7.54--
Aditxt Inc506.45k-41.45m3.20m47.00--0.322--6.31-109.80-109.800.74885.960.02840.92961.3410,775.53-231.82-192.78-658.00-321.59-27.22---8,149.75-7,208.650.0562-3.420.3915---30.90---18.11------
Avenue Therapeutics Inc0.00-7.18m3.24m3.00--0.7159-----39.36-39.360.004.810.00----0.00-123.08-186.91-1,045.52-287.70------------0.00-------192.15------
Optimus Healthcare Services Inc1.27m-7.79m3.32m17.00------2.62-0.1948-0.19480.0317-0.12910.2595--2.1674,453.53-159.79---2,228.37--77.90---615.77--0.1525-15.4121.18--------------
Livewire Ergogenics Inc67.98k-1.09m3.35m1.00------49.25-0.0061-0.00610.0003-0.00220.19791.742.8667,980.00-317.45-------113.70---1,604.38--0.1248-2.13----68.58---3.64------
Manuka Inc671.00k-1.14m3.36m4.00------5.01-0.0128-0.01280.0066-0.01242.410.941237.28167,750.00-410.43-463.75----88.08---170.04-732.150.0194-----------854.23------
Gold River Productions Inc.-100.00bn-100.00bn3.37m1.00k--5.19----------0.0005----------------------------0.00-------100.11------
Data as of Jun 06 2024. Currency figures normalised to Revelation Biosciences Inc's reporting currency: US Dollar USD

Institutional shareholders

0.47%Per cent of shares held by top holders
HolderShares% Held
UBS Securities LLCas of 31 Mar 20244.18k0.26%
Tower Research Capital LLCas of 31 Mar 20243.12k0.19%
Securities America Advisors, Inc.as of 31 Mar 2024300.000.02%
RBC Dominion Securities, Inc.as of 31 Mar 202436.000.00%
Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 20245.000.00%
Wells Fargo Bank, NA (Private Banking)as of 31 Mar 20243.000.00%
POM Investment Strategies LLCas of 31 Mar 20241.000.00%
AXA Investment Managers UK Ltd.as of 31 Mar 20240.000.00%
Walleye Capital LLCas of 31 Mar 20240.000.00%
Geode Capital Management LLCas of 31 Mar 20240.000.00%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.